Why Assertio (ASRT) Stock Is Volatile Today
Portfolio Pulse from Henry Khederian
Assertio Holdings Inc (ASRT) shares are trading higher by 12.48% after the company reported Q2 financial results and withdrew its 2023 financial outlook due to the recent approval of a generic indomethacin suppository by the U.S. FDA. Zydus Lifesciences Limited received the approval and has been granted a CGT designation and 180-day CGT exclusivity to market the product.
August 07, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ASRT's stock price increased following Q2 results and the withdrawal of its 2023 outlook due to the approval of a generic drug by the FDA. This could lead to increased competition for ASRT.
The rise in ASRT's stock price is likely due to the company's Q2 results. However, the withdrawal of its 2023 outlook and the approval of a generic drug by the FDA could lead to increased competition, which may impact the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100